Low total cholesterol blood level is correlated with pulmonary severity in COVID-19 critical ill patients

Ressaire, Quentin; Dudoignon, Emmanuel; Moreno, Nabila; Coutrot, Maxime; Dépret, François

doi:10.1016/j.accpm.2020.07.015

Cited by 10 publications

(9 citation statements)

References 5 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As observed with other infections numerous studies have reported a decrease in total cholesterol, LDL-C, and HDL-C levels and variable changes in triglycerides in patients with COVID 19 infections ( 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 ). As expected, apolipoprotein A-I and B were also decreased ( 39 , 40 , 41 ). With recovery from COVID-19 infection the lipid levels return towards levels present prior to infection ( 28 , 29 , 30 , 42 , 43 ).…”

Section: Effect Of Infections On Lipid and Lipoproteinssupporting

confidence: 77%

“…Low LDL-C and/or HDL-C levels at admission to the hospital predict an increased risk of developing a severe disease. Increased mortality was observed in patients with low total cholesterol, LDL-C, and/or HDL-C levels at admission to the hospital and in these very ill patient’s lipid levels continued to decline during the hospitalization ( 28 , 36 , 38 , 41 , 43 , 44 , 45 ). A single study reported that the time to develop a negative RT-PCR test for SARs-CoV-2 was increased in patients with low HDL-C levels ( 46 ).…”

Section: Effect Of Infections On Lipid and Lipoproteinsmentioning

confidence: 99%

See 1 more Smart Citation

The bidirectional link between HDL and COVID-19 infections

Feingold

2021

Journal of Lipid Research

View full text Add to dashboard Cite

Section: Effect Of Infections On Lipid and Lipoproteinssupporting

confidence: 77%

Section: Effect Of Infections On Lipid and Lipoproteinsmentioning

confidence: 99%

The bidirectional link between HDL and COVID-19 infections

Feingold

2021

Journal of Lipid Research

View full text Add to dashboard Cite

“…In this context, high-density and low-density lipoprotein cholesterol and total cholesterol levels were reported to be significantly decreased in COVID-19 patients (Ressaire, Dudoignon, Moreno, Coutrot, & Dépret, 2020; G. Wang et al, 2020 ). Low cholesterol levels were correlated with a higher risk of developing severe events or longer recovery times in some studies ( X. Ding et al, 2020 ; Ressaire, Dudoignon, Moreno, Coutrot, & Dépret, 2020 ; G. Wang et al, 2020 ), but not in another one ( Tanaka et al, 2020 ).…”

Section: Cholesterol Reducing Drugs and Ace2mentioning

confidence: 87%

A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor

Öz

Lorke

Kabbani

2021

Pharmacology & Therapeutics

View full text Add to dashboard Cite

The recent emergence of coronavirus disease-2019 (COVID-19) as a global pandemic has prompted scientists to address an urgent need for defining mechanisms of disease pathology and treatment. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent for COVID-19, employs angiotensin converting enzyme 2 (ACE2) as its primary target for cell surface attachment and likely entry into the host cell. Thus, understanding factors that may regulate the expression and function of ACE2 in the healthy and diseased body is critical for clinical intervention. Over 66% of all adults in the United States are currently using a prescription drug and while earlier findings have focused on possible upregulation of ACE2 expression through the use of renin angiotensin system (RAS) inhibitors, mounting evidence suggests that various other widely administered drugs used in the treatment of hypertension, heart failure, diabetes mellitus, hyperlipidemias, coagulation disorders, and pulmonary disease may also present a varied risk for COVID-19. Specifically, we summarize mechanisms on how heparin, statins, steroids and phytochemicals, besides their established therapeutic effects, may also interfere with SARS-CoV-2 viral entry into cells. We also describe evidence on the effect of several vitamins, phytochemicals, and naturally occurring compounds on ACE2 expression and activity in various tissues and disease models. This comprehensive review aims to provide a timely compendium on the potential impact of commonly prescribed drugs and pharmacologically active compounds on COVID-19 pathology and risk through regulation of ACE2 and RAS signaling.

show abstract

“…Ressaire et al examined the lipid profile of 31 out of 54 COVID-19 patients admitted to the ICU [ 31 ]. On admission, total patients' HDL-C levels were lower than the normal reference [27.8 mg/dL (23.6–40.0)].…”

Section: Resultsmentioning

confidence: 99%

“…Notably, among those, non-survivors (n = 7) had lower values of HDL levels [25.9 mg/dL (24.0–42.5)] compared with the 24 patients in the survivor group [32.9 mg/dL (18.2–50.3), p < 0.28]. Although no significant difference on HDL-C levels was observed, LDL-C and TCHOL levels were significantly lower in non-survivors compared with survivors ( p = 0.004 and p = 0.007, respectively) [ 31 ].…”

Section: Resultsmentioning

confidence: 99%

High-density lipoprotein cholesterol: A marker of COVID-19 infection severity?

Agouridis

Pagkali

Ζιντζαράς

et al. 2021

Atherosclerosis Plus

View full text Add to dashboard Cite

Background and aims To systematically address all the relevant evidence of the association between high-density lipoprotein cholesterol (HDL-C) and COVID-19 infection. Methods We searched PubMed, PubMed Central and medRxiv databases (up to May 2021) for studies related to HDL-C and COVID-19 infection. A qualitative synthesis of published prospective and retrospective studies for the role of low HDL-C levels on COVID-19 infection severity was performed. Results Thirty-three studies (6 prospective, 27 retrospective) including 11,918 COVID-19 patients were eligible for the systematic review. Twelve studies compared HDL-C levels on admission in COVID-19 patients with healthy controls. In these 12 studies, COVID-19 patients had significantly lower HDL-C levels on admission compared with that of healthy controls. Twenty-eight studies observed the HDL-C levels among COVID-19 diagnosed patients, to establish the role of low HDL-C values in the prognosis of the infection. Twenty-four studies showed a correlation between low HDL-C levels with disease severity, while only 4 studies showed no association. Conclusions Low HDL-C levels should be added in the list of the others well-known risk factors for COVID-19 severity.

show abstract

Low total cholesterol blood level is correlated with pulmonary severity in COVID-19 critical ill patients

Cited by 10 publications

References 5 publications

The bidirectional link between HDL and COVID-19 infections

The bidirectional link between HDL and COVID-19 infections

A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor

High-density lipoprotein cholesterol: A marker of COVID-19 infection severity?

Contact Info

Product

Resources

About